Letters Section Editor: Robert M. Golub, MD, Senior Editor.
In Reply: In our Editorial, we focused on breast cancer chemoprevention as the basis of therapy. Dr Goldstein illustrates that there are individual cases in which raloxifene is a superior choice of therapy. Similarly, there are cases in which tamoxifen may be a better choice. Patient preference and issues related to cost or confidence in the long-term sequelae of tamoxifen therapy may influence a patient to choose, with her physician, tamoxifen over raloxifene.
Gradishar WJ, Cella D. Raloxifene vs Tamoxifen—Reply. JAMA. 2007;297(3):263-264. doi:10.1001/jama.297.3.264-a